Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Par Pharmaceutical was founded in New York in 1978. Many products are licensed-in from other generic manufacturers, such as Genpharm or Spectrum, or originator companies. Par has concluded a number of authorised generic agreements with originators, most recently with AstraZeneca for metoprolol ER.

Par's in-house manufacturing capabilities revolve principally around Kali Laboratories, a company acquired in 2004. Both companies hold a number of ANDAs under their own name. The most recent drugs to be approved are ondansetron, a version of Merck's Zofran, and amlodipine besylate, a version of Pfizer's Norvasc.

The company boosted its position in the US market in 2006, through the purchase of a number of drugs from Teva and IVAX. This was mandated by the FTC as a condition of the merger between the latter two companies.